LUCIUS 卢修斯 奎扎替尼 Quizartinib急性髓性白血病

奎扎替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Quizartinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:
Each film-coated tablet contains Quizartin

急性髓性白血病

uyurocmonec s0 ing couivalent to

LUCiUS

Vuzartino .........
Indication:

......................... 26.3mg.

PHARMACEUTICALS

LuciQuiza is a kinase inhibitor indicareu
combination with standaro
standard cytarabine and

anthracycline induction and cytarabina
colisondauon, and as maintenance monotherapy
following consalidation chematherany for
treatmont of adult waionte nih natsy diasnosed acut

LuciQuiza

myeloid leukemia (AML) that
tandem cuplication (ITD)-positive as detected by an
Dosage and Use
. Take LuciQuiza tablets orally once daily with or

Quizartinib Tablets

FDA批准

ithout food at approximately the same time each
·See Full Prescribing Information for recommended
LuciQuiza dosage regimen and dosage

26.5mg

Storage: in a dry place and store at 20°C to 25°C
Warning:
Keep medicine out of reach of Children. Do not
administer LuciQuiza during Pregnancy and

Rx Only

PLEASESEE PACKAGE INSERT
Manufactured and Marketed b
LUCIUS

权威认证

Thongmang village. Xaythany district
vientiane Capital, Laos
www.lucius.la
Warning: Tohe cold hy
of ersc oy retail on prescription
byfosyoicians only, and as directed
y the physician

14 Tablets

口碑质量

适应症:
适用于治疗经FDA批准的测试方法检测为FLT3内串联重复
(ITD)阳性的新诊断急性髓系白血病(AML)成年患者。在诱导
治疗中可与阿糖胞苷和蒽环类联合使用,单药可用于巩固化
疗后的维持治疗。
推荐剂量:
1、奎扎替尼的推荐剂量和剂量调整方案,请阅读说明书。
2、每日口服一次,大约在同一时间服用,随餐或空腹均可。